computer-aided-drug-design
(3)
Numerion Labs
Numerion Labs (formerly Atomwise) is an AI-native drug discovery company that pioneered the use of deep learning for structure-based drug design. Its AI chemistry superplatform - built on the COSMOS foundation model, the APEX hyper-scalable enumerator, and EXPO optimization algorithms - explores billions of drug-like molecules to find and optimize novel chemical matter. Based in San Francisco with a San Diego presence, the company is advancing its own pipeline of small-molecule programs in immune and inflammatory disease while collaborating with partners across the pharmaceutical industry.
Keythera Pharmaceuticals Co., Ltd
Keythera (Suzhou) Biopharmaceuticals is a clinical-stage biotech building first-in-class small molecule drugs for cancer and autoimmune disease. Its core edge is ADMS - Affinity Detection by Mass Spectroscopy - an affinity-based high-throughput screening platform that can screen up to 250,000 compounds per day per workstation and fuses bioinformatics, structural chemistry, computer-aided drug design and AI to find and optimize drug candidates faster and at lower risk. Founded in 2020 by industry veteran Dr. Yongqi Deng, the company has built six pipelines, advanced its lead EP4 antagonist KF-0210 into the clinic, and raised roughly RMB 100M in Series A funding.
Steve Worland
Steve Worland, Ph.D., is the CEO of Numerion Labs, the AI-native drug discovery company that grew out of Atomwise. A medicinal-chemistry lifer with three decades behind him, his bench work fed the discovery of Paxlovid and Inlyta, and his operating record runs from Agouron through a Roche acquisition to a SPAC. Now he is betting that deep-learning surrogates plus GPU enumeration can search billions of molecules in seconds.